Anthem (NYSE:ANTM) had its target price hoisted by Morgan Stanley from $359.00 to $371.00 in a report published on Friday morning, BenzingaRatingsTable reports. The brokerage currently has an overweight rating on the stock.
Several other equities analysts have also recently commented on ANTM. Citigroup reaffirmed a buy rating on shares of Healthequity in a report on Friday, May 10th. Cantor Fitzgerald reaffirmed a buy rating and issued a $75.00 price target on shares of Emergent Biosolutions in a report on Sunday, April 21st. UBS Group set a $36.00 price target on Halliburton and gave the company a buy rating in a report on Tuesday, April 23rd. Barclays upped their price target on T. Rowe Price Group from $90.00 to $95.00 and gave the company an underweight rating in a report on Thursday, April 25th. Finally, Zacks Investment Research cut G1 Therapeutics from a buy rating to a hold rating in a report on Thursday, May 16th. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $325.67.
Anthem stock opened at $306.85 on Friday. The firm has a 50 day moving average price of $285.29. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.61 and a current ratio of 1.61. The firm has a market cap of $78.92 billion, a PE ratio of 19.31, a price-to-earnings-growth ratio of 1.10 and a beta of 0.70. Anthem has a 12 month low of $227.16 and a 12 month high of $317.99.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 25th. Investors of record on Monday, June 10th were given a dividend of $0.80 per share. The ex-dividend date was Friday, June 7th. This represents a $3.20 dividend on an annualized basis and a yield of 1.04%. Anthem’s dividend payout ratio (DPR) is presently 20.14%.
In other Anthem news, SVP Ronald W. Penczek sold 763 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $279.00, for a total value of $212,877.00. Following the transaction, the senior vice president now directly owns 2,295 shares in the company, valued at approximately $640,305. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas C. Zielinski sold 8,826 shares of the stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $283.92, for a total value of $2,505,877.92. Following the completion of the transaction, the executive vice president now owns 33,183 shares in the company, valued at $9,421,317.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,245 shares of company stock worth $3,174,155. 0.17% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Brighton Jones LLC boosted its position in shares of Anthem by 3.7% in the 1st quarter. Brighton Jones LLC now owns 1,082 shares of the company’s stock worth $311,000 after purchasing an additional 39 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Anthem by 15.3% in the 1st quarter. Lindbrook Capital LLC now owns 362 shares of the company’s stock worth $103,000 after purchasing an additional 48 shares during the last quarter. Foundations Investment Advisors LLC boosted its position in shares of Anthem by 6.6% in the 1st quarter. Foundations Investment Advisors LLC now owns 810 shares of the company’s stock worth $232,000 after purchasing an additional 50 shares during the last quarter. NewSquare Capital LLC boosted its position in shares of Anthem by 5.3% in the 1st quarter. NewSquare Capital LLC now owns 985 shares of the company’s stock worth $283,000 after purchasing an additional 50 shares during the last quarter. Finally, Waldron Private Wealth LLC boosted its position in shares of Anthem by 6.4% in the 1st quarter. Waldron Private Wealth LLC now owns 842 shares of the company’s stock worth $241,000 after purchasing an additional 51 shares during the last quarter. Hedge funds and other institutional investors own 87.09% of the company’s stock.
Anthem, Inc, through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets.
Further Reading: Federal Reserve
Receive News & Ratings for Anthem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthem and related companies with MarketBeat.com's FREE daily email newsletter.